Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00057993
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Target Recruit Count
- 4400
- Registration Number
- NCT00032136
- Locations
- 🇬🇧
City Hospital - Birmingham, Birmingham, England, United Kingdom
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1598
- Registration Number
- NCT00016432
- Locations
- 🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Center for Oncology Research and Treatment, Medical City Hospital, Dallas, Texas, United States
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
- Conditions
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00040014
- Locations
- 🇬🇧
Pfizer Investigational Site, Leicester, United Kingdom
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4740
- Registration Number
- NCT00038467
- Locations
- 🇬🇧
Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2010-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00038103
- Locations
- 🇵🇭
Pfizer Investigational Site, Manila, Philippines
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.